IL6 and neoplasm: In fact, recent data demonstrated how anti-PD-1 antibodies failed to induce tumor regression in mice without STK11 but exposing them to an interleukin-6 antibody (a pro-inflammatory cytokine secreted by tumor-infiltrating neutrophils) or neutrophil-depleting antibody yielded T cell infiltration and therapeutic benefits [189].